Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Obesity impairs sodium excretion through multiple mechanisms (RAAS activation, leptin effects, inflammatory signaling)
Figure 5 summarises the 5-year outcomes of interest
Specifically, the company states that FDA-approved GLP-1/GIP medications for weight loss and type 2 diabetes, including Ozempic, Wegovy, Zepbound, and Mounjaro, "may also be eligible for coverage." The company further states that while they "assist with prior authorizations and prescription submissions," they "do not bill insurance directly." This distinction is important: the compounded GLP-1 program itself is described as a cash-pay arrangement, but the company also facilitates access to FDA-approved branded medications that may have insurance pathways
Anecdotal reports include increased tooth decay, gum inflammation, tooth sensitivity, dry mouth, bad breath, and tooth discolouration
